Contents {#rth212368-sec-0001}
========

Robert AriensFibrin Microfilms Protect Clots From MicrobesCecilia BecattiniManaging DOACs in EmergenciesMarkus BenderPlatelet Cytoskeleton and Its DisordersWolfgang BergmeierSmall GTPases in Megakaryocyte and Platelet BiologyElisabetta CastoldiAnticoagulant Factor VKatrien DevreeseLaboratory Diagnosis of Antiphospholipid SyndromeMartin EllisMyeloproliferative Neoplasms in Pregnancy: Implications for Mother and ChildDavid GailaniClinical Heterogeneity in FXI DeficiencyVera IgnjatovicProteomics of the Hemostatic SystemPaula D. JamesVon Willebrand Factor in Angiogenesis and Angiodysplasia in PatientsSteven KerriganSepsis: Vascular Endothelial Cell Dysfunction During SepsisMichele LambertClinical Versus Genetic Approach to the Diagnosis of Platelet Function DisordersLai Heng LeeObstetric Antiphospholipid SyndromeMarcel LeviDrug‐Associated Thrombotic Microangiopathies: Emerging Toxicities of Novel DrugsNorma MaugeriPlatelet‐Derived Microparticles in Autoimmune DiseasesJoost MeijersTAFI Pathway in HemophiliaJuan Melero‐MartinCell Therapy Using Endothelial Progenitor CellsAlan D. MichelsonWhen and How to Use Antiplatelet Agents in ChildrenFederico MingozziImmunogenicity of Adeno‐Associated VectorsKeith NeevesComputationally Driven Discovery in Coagulation DynamicsHeyu NiGPIbα‐ Drive Force for Liver Thrombopoietin GenerationAnna‐Karin OlssonThe Role of Platelets in Tumor Vessel Integrity and MetastasisZoltán ProhászkaTreatment of Complement‐Mediated Thrombotic MicroangiopathiesMarie RansonFibrinolytic Factors in Cancer ProgressionNicoletta RivaDOACs for Unusual Site Venous ThromboembolismYotis SenisTyrosine Kinases/Phosphatases and Platelet ActivationCornelia H. van OmmenDOACs in Children: Current Evidence and Future PerspectivesDouglas E. VaughanPAI‐1 and the Multi‐Morbidity of AgingJohn WeiselVisualizing Thrombosis to Improve Thrombolysis

Fibrin microfilms protect clots from microbes {#rth212368-sec-0002}
=============================================

Robert Ariȹns PhD

When thrombin cleaves fibrinogen, the resulting fibrin was known to spontaneously polymerize into protofibrils that aggregate and branch to form fibrin fibers. The fibrin fibers provide the structural and elastic backbone to the blood clot. Our recent study has shown that fibrin can also produce Langmuir‐Blodgett films at phase boundaries (eg the liquid/air interface).[^1^](#rth212368-bib-0001){ref-type="ref"} These fibrin films help to trap host cells into the clot, and prevent microbial infection from entering the clot to infect the host. Films have also been observed on intracoronary thrombi obtained by thrombectomy from patients with myocardial infarction,[^2^](#rth212368-bib-0002){ref-type="ref"} and from clots obtained by stent retriever from patients with ischemic stroke.[^3^](#rth212368-bib-0003){ref-type="ref"} Films or shell‐like structures in intravascular thrombi have been reported to slow down thrombolysis,[^3^](#rth212368-bib-0003){ref-type="ref"} but their origin and full functional role(s) require further investigation.

Managing DOACs in emergencies {#rth212368-sec-0003}
=============================

Cecilia Becattini MD, PhD

Clinicians should tailor treatment of patients with emergencies occurring while on treatment with direct oral anticoagulants (DOACs) based on the severity of major bleeding and the need for emergency access to the operative room.[^4^](#rth212368-bib-0004){ref-type="ref"}, [^5^](#rth212368-bib-0005){ref-type="ref"} Interruption of DOACs and general supportive measures should be considered while trying to confirm that anticoagulant treatment has a role in bleeding and/or in deciding the timing of surgery. Time and dose of last intake, renal function, and the measurement of plasma levels of DOAC, if available, should be considered.[^6^](#rth212368-bib-0006){ref-type="ref"} If measurement of plasma levels of DOAC is not feasible, standard coagulation tests can be useful to assess DOAC‐related anticoagulation.

No evidence on the effect of idarucizumab and andexanet in survival has been reported so far. Effective hemostasis is assessed by methods developed for assessment of prothrombin complex concentrates in warfarin reversal for andexanet and by diluted thrombin time or ecarin clotting time for idarucizumab.[^4^](#rth212368-bib-0004){ref-type="ref"}, [^5^](#rth212368-bib-0005){ref-type="ref"}

Platelet cytoskeleton and its disorders {#rth212368-sec-0004}
=======================================

Markus Bender PhD

For references, see Hartwig[^7^](#rth212368-bib-0007){ref-type="ref"} and Schurr et al.[^8^](#rth212368-bib-0008){ref-type="ref"}

Small GTPases in megakaryocyte and platelet biology {#rth212368-sec-0005}
===================================================

Wolfgang Bergmeier PhD

Anticoagulant factor V {#rth212368-sec-0006}
======================

Elisabetta Castoldi PhD

It is common knowledge that activated factor V (FVa) expresses procoagulant activity as an essential cofactor of factor Xa (FXa) in prothrombin (PT) activation. What is less appreciated is that as long as it is not (fully) activated, FV contributes to the anticoagulant cause by (i) maintaining tissue factor pathway inhibitor‐α (TFPIα) in the circulation; (ii) enhancing the inhibition of FXa by TFPIα and protein S (PS); and (iii) stimulating the inactivation of factor VIIIa (FVIIIa) by activated protein C (APC) and PS. The first 2 anticoagulant functions are most pronounced in FV‐short, a FV splicing variant present in plasma at sub‐nM concentrations. The third anticoagulant function requires cleavage of single‐chain FV by APC. The physiopathological relevance of these anticoagulant mechanisms is underscored by genetic defects that enhance (FV East‐Texas) or impair (FV Leiden) the anticoagulant properties of FV, thereby increasing the risk of bleeding or venous thrombosis.[^9^](#rth212368-bib-0009){ref-type="ref"}

Laboratory diagnosis of antiphospholipid syndrome {#rth212368-sec-0007}
=================================================

Katrien M. J. Devreese MD, PhD

The diagnosis of antiphospholipid syndrome (APS) relies on detection of antiphospholipid antibodies (APAs). APAs are a heterogeneous group of antibodies, but only lupus anticoagulant (LAC), anticardiolipin (aCL) and anti‐β2‐glycoprotein I antibodies (aβ2GPI) IgG or IgM are included in the laboratory criteria. At least 1 criterion has to be persistently positive.[^10^](#rth212368-bib-0010){ref-type="ref"} LAC measurement remains a complex procedure with a 3‐step procedure, including screening, mixing, and confirmatory tests in 2 test systems. Solid‐phase assays for aCL and aβ2GPI show interassay differences. These methodological issues make the laboratory diagnosis of APS challenging, although progress has been made on the standardization and interpretation as reflected in published guidelines on LAC testing and solid‐phase assays for aCL and aβ2GPI.[^10^](#rth212368-bib-0010){ref-type="ref"}, [^11^](#rth212368-bib-0011){ref-type="ref"}, [^12^](#rth212368-bib-0012){ref-type="ref"} Other APAs, not included in the current criteria, such as antibodies against the domain I of β2GPI and antiphosphatidylserine‐prothrombin antibodies may be useful in risk stratification but have no added value for diagnosis of APS.

Myeloproliferative neoplasms in pregnancy: Implications for mother and child {#rth212368-sec-0008}
============================================================================

Martin H. Ellis MD

Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (termed *myeloproliferative neoplasms* \[MPNs\]) are clonal diseases that may result in fatal end‐stage bone marrow fibrosis or acute leukemia. During the long natural history of these diseases, particularly PV and ET, thrombosis is an important complication.

The median age at diagnosis of the MPNs is \>60 years; however, 20% are \<40 years old when diagnosed. Thus, there is a need to provide appropriate treatment to pregnant patients with MPNs.

Maternal (venous or arterial thrombosis or hemorrhage), or placenta‐related (fetal loss or preeclampsia/eclampsia) complications may occur during pregnancy. The incidence and risk factors for complications are poorly defined.

Treatment has been observational data and expert opinion based. Recently a meta‐analysis of randomized clinical trials has provided a basis for decision making; however, more data from prospective or registry studies is required to inform appropriate treatment for these patients.[^13^](#rth212368-bib-0013){ref-type="ref"}

Clinical heterogeneity in factor XI deficiency {#rth212368-sec-0009}
==============================================

David Gailani MD

Factor XI (FXI) is the precursor of FXIa, a protease that contributes to thrombin generation by activating factor IX.[^14^](#rth212368-bib-0014){ref-type="ref"} While critical to clotting in the activated partial thromboplastin time assay, FXI makes modest contributions to hemostasis.[^15^](#rth212368-bib-0015){ref-type="ref"} Furthermore, bleeding in FXI‐deficient patients correlates poorly with plasma FXI levels.[^15^](#rth212368-bib-0015){ref-type="ref"} Indeed, completely deficient patients may not experience abnormal bleeding. Thrombin generation is controlled by a group of vitamin K--dependent proteases and their cofactors.[^16^](#rth212368-bib-0016){ref-type="ref"} The process is initiated at an injury site by a complex of factor VIIa and tissue factor (TF). In this scheme, FXI serves an ancillary role, supplementing factor IXa generated by VIIa/TF.[^16^](#rth212368-bib-0016){ref-type="ref"} Given this, it seems likely that a number of processes that alter thrombin generation, platelet activity, or fibrinolysis would affect the requirement for FXIa activity in different individuals, and in different tissues. Contributors to variable bleeding in FXI‐deficiency may well be similar to those that influence bleeding in people with hemophilia.

Proteomics of the hemostatic system {#rth212368-sec-0010}
===================================

Vera Ignjatovic PhD

Proteomics, as the study of proteins as the functional elements and main drivers of phenotype, is extremely important when it comes to understanding developmental biology. In addition, proteomics, via biomarker discovery, allows for early detection of disease. However, proteomics has, at least until very recently, been underutilized in the setting of thrombosis and hemostasis. We have recently used a proteomics approach to characterise age‐specific changes in the hemostatic plasma proteins. This figure outlines age‐specific changes in expression of 27 proteins that are associated with coagulation and/or serve as markers of platelet activation or endothelial involvement. Holistic proteomic analysis in the background of dynamic, age‐specific nature of hemostasis yields new insights and sets a new standard for using proteomics in thrombosis and hemostasis.[^17^](#rth212368-bib-0017){ref-type="ref"}

von Willebrand factor in angiogenesis and angiodysplasia in patients {#rth212368-sec-0011}
====================================================================

Paula D. James MD

Angiodysplasia is increased in patients with congenital von Willebrand disease (VWD) and acquired von Willebrand syndrome (AVWS). Both groups of patients experience intractable gastrointestinal bleeding that is often very difficult to treat. Previous studies have shown that endothelial von Willebrand factor (VWF) is a negative regulator of angiogenesis.[^18^](#rth212368-bib-0018){ref-type="ref"} Patient derived endothelial colony‐forming cells from both patients with type 3 VWD and patients with aortic stenosis (AVWS) display abnormal angiogenesis in vitro.[^19^](#rth212368-bib-0019){ref-type="ref"}, [^20^](#rth212368-bib-0020){ref-type="ref"} In vivo studies in VWF knockout mice show increased vessel growth in the ears and increased tubule formation in Matrigel plugs at 7 days when compared with wild type.

Vascular endothelial cell dysregulation during sepsis {#rth212368-sec-0012}
=====================================================

Steve Kerrigan PhD

Sepsis is of significant global concern with 49 million new cases of sepsis worldwide per year and 11 million deaths.[^21^](#rth212368-bib-0021){ref-type="ref"} Sepsis is defined as a life‐threatening organ dysfunction caused by a dysregulated host response to infection. The vascular endothelium is a major target of sepsis‐induced events.[^22^](#rth212368-bib-0022){ref-type="ref"} Pathogen binding to the vascular endothelium is seen as a pivotal step in driving the dysregulated response to the infection. For example, endothelial dysregulation results in dysfunction of anticoagulation and places the system into a hypercoagulant state. A breakdown of the endothelial barrier results in dissemination of bacteria to distant sites and fluid leakage into the extravascular space leading to life‐threatening edema in the lungs, kidney, and brain that can progress to multiorgan failure.[^22^](#rth212368-bib-0022){ref-type="ref"} The vascular endothelium is therefore a major target of novel therapies to disrupt pathogen attachment in an attempt to slow or stop progression of sepsis to a life‐threatening situation.[^23^](#rth212368-bib-0023){ref-type="ref"}

Clinical versus genetic approaches to the diagnosis of platelet function disorders {#rth212368-sec-0013}
==================================================================================

Michele P. Lambert MD, MSTR

Requires the coordination of laboratory evaluation *with* genetic testing:Improve patient outcomesIncrease knowledgeGuidelines are needed that reflect this recommendation:Make this the *standard of care*Provide access to testingRequire genetic counseling

Obstetric antiphospholipid syndrome {#rth212368-sec-0014}
===================================

Lai Heng Lee MBBS, M Med, FAMS (Int Med), FRCP (UK)

For references see Miyakis et al,[^24^](#rth212368-bib-0024){ref-type="ref"} Alijotis‐Reig et al,[^25^](#rth212368-bib-0025){ref-type="ref"} and Ruffatti et al.[^26^](#rth212368-bib-0026){ref-type="ref"}

Drug‐associated thrombotic microangiopathies: Emerging toxicities of novel drugs {#rth212368-sec-0015}
================================================================================

Marcel Levi MD, PhD, FRCP

For references see Pisoni et al,[^27^](#rth212368-bib-0027){ref-type="ref"} Kreuter and Winters,[^28^](#rth212368-bib-0028){ref-type="ref"} and Levi and Sivapalaratnam.[^29^](#rth212368-bib-0029){ref-type="ref"}

Platelet‐derived microparticles in autoimmune diseases {#rth212368-sec-0016}
======================================================

Norma Maugeri PhD

TAFI pathway in hemophilia {#rth212368-sec-0017}
==========================

Joost Meijers PhD

For references, see Wyseure et al[^30^](#rth212368-bib-0030){ref-type="ref"}, [^31^](#rth212368-bib-0031){ref-type="ref"} and Semeraro et al.[^32^](#rth212368-bib-0032){ref-type="ref"}

Cell therapy using endothelial progenitor cells {#rth212368-sec-0018}
===============================================

Juan Melero‐Martin PhD

Human induced pluripotent stem cell (iPSC)--derived endothelial cells (iECs) have become a valuable tool in regenerative medicine. Our group has recently developed an application for the treatment of hemophilia A that entails bioengineering patient‐specific microvascular grafts for the delivery of full‐length factor VIII into the bloodstream.[^33^](#rth212368-bib-0033){ref-type="ref"} To this end, we first generated patient‐specific iPSCs from urine epithelial cells and genetically modified them using a nonviral *piggyBac* DNA transposon system to insert multiple copies of the full‐length *F8* gene. We subsequently differentiated the modified F8‐iPSCs into competent F8‐iECs and demonstrated that the cells were capable of producing high levels of FVIII. Importantly, following subcutaneous implantation into immunodeficient hemophilic (SCID‐f8ko) mice, we demonstrated that the F8‐iECs were able to self‐assemble into vascular networks, and that the newly formed microvessels had the capacity to deliver functional FVIII directly into the bloodstream of the mice, effectively correcting the clotting deficiency.

When and how to use antiplatelet agents in children {#rth212368-sec-0019}
===================================================

Alan D. Michelson MD

Immunogenicity of adeno‐associated vectors {#rth212368-sec-0020}
==========================================

Federico Mingozzi PhD

The adeno‐associated virus (AAV) vector gene‐transfer platform has an attractive safety and long‐term efficacy profile demonstrated in a number of trials for hemophilia A and B. Because humans are naturally exposed to wild‐type AAV, they develop both antibody and T‐cell immunity to the virus. AAV vectors, like their wild‐type counterpart, interact with the host immune system at multiple levels, starting early after vector administration with the induction of innate immune responses. Early activation of immunity is followed by adaptive immune responses, which result in long‐term development of neutralizing antibodies and activation of capsid T‐cell responses directed against the vector capsid. When not adequately managed, immune responses to AAV vectors can be associated with short‐lived or absent expression of the therapeutic transgene.[^34^](#rth212368-bib-0034){ref-type="ref"}

Computationally driven discovery in coagulation dynamics {#rth212368-sec-0021}
========================================================

Keith Neeves PhD

For references, see Link et al[^35^](#rth212368-bib-0035){ref-type="ref"}, [^36^](#rth212368-bib-0036){ref-type="ref"} and Biorender.com.[^37^](#rth212368-bib-0037){ref-type="ref"}

GPIbα‐driving force for liver thrombopoietin generation {#rth212368-sec-0022}
=======================================================

Heyu Ni MD, PhD

Platelet GPIbα plays important roles in thrombosis and hemostasis, but its role in thrombopoietin (TPO) generation was not previously explored. TPO is predominantly produced by the liver, and its circulating levels have been thought to be maintained through its clearance by platelets and megakaryocytes via surface c‐Mpl internalization. Unexpectedly, we found TPO levels have a 2‐ to 3‐fold decrease in both GPIbα deficient mice and human patients with Bernard‐Soulier syndrome (BSS). Transfusion of platelets from wild‐type but not GPIbα‐/‐ or interleukin‐4/GPIbα transgenic mice increased the TPO level in GPIbα‐/‐ mice via de novo TPO synthesis in the liver. In vitro cell culture assays further demonstrate GPIbα‐hepatocyte interaction is the driving force for TPO generation, which can be inhibited by antibodies blocking the N‐terminus of GPIbα. These findings may have important implications in diseases related to GPIbα such as BSS and immune‐mediated thrombocytopenia. We are studying the molecular and cellular mechanisms behind this "driving force."[^38^](#rth212368-bib-0038){ref-type="ref"}, [^39^](#rth212368-bib-0039){ref-type="ref"}, [^40^](#rth212368-bib-0040){ref-type="ref"}

The role of platelets in tumor metastasis {#rth212368-sec-0023}
=========================================

Anna‐Karin Olsson MD, PhD

Platelets activated in the tumor microenvironment secrete platelet‐derived growth factor subunit B (PDGFB) that contributes to the vascular remodeling process. (A) In healthy tissue, platelets stay in the circulation in a nonactivated state, since they do not come in contact with subendothelial components such as tissue factor (TF) and collagen. (B) In contrast, the discontinuous endothelium in tumors expose platelets to subendothelial spaces, leading to their activation and degranulation in close proximity to the vasculature. Platelet‐derived PDGFB will, in the same was as endothelial‐derived PDGFB, be retained close to the vasculature due to the heparan sulfate--binding retention‐motif and contribute to the pericyte‐recruiting gradient of PDGFB.

Treatment of complement‐mediated thrombotic microangiopathies {#rth212368-sec-0024}
=============================================================

Zoltán Prohászka MD

Thrombotic microangiopathies (TMAs) are heterogeneous diseases with common pathogenic features including endothelial activation and damage, aggregation and consumption of platelets, and hemolysis consequent to mechanical injury to erythrocytes (1). TMAs are rapidly progressing diseases when untreated; therefore, the decision to start the initial, lifesaving treatment should be done quickly, based on clinical and laboratory signs and careful evaluation of the presenting features (2). However, since various targeted therapies are now available to target the molecular etiologic factors or key pathogenic mediators of TMAs, it is of utmost importance to rapidly evaluate the molecular etiology behind TMAs and make discrimination between complement‐mediated disease forms including, for example, atypical hemolytic uremic syndrome (aHUS) and other forms of TMAs (2 and 3). First‐line therapy of aHUS in pediatric patients is based on complement inhibitory drugs, and for adults, early change from plasmapheresis to complement inhibitory therapy is indicated in case of plasma resistance or plasma dependence (3). There are attempts to identify factors (including rare or common variants of complement genes) that may help facilitate decisions on the length of complement inhibitory therapy (4). For those necessitating kidney transplantation due to complement‐mediated TMA, peritransplantation management, including the application of complement inhibitory drugs, should be based on careful genetic evaluation of complement factors and regulators (5).

Fibrinolytic factors in cancer progression {#rth212368-sec-0025}
==========================================

Marie Ranson PhD

For references, see Harris et al,[^41^](#rth212368-bib-0041){ref-type="ref"} Stutchbury et al,[^42^](#rth212368-bib-0042){ref-type="ref"} and Buckley et al.[^43^](#rth212368-bib-0043){ref-type="ref"}

DOACs for unusual site venous thromboembolism {#rth212368-sec-0026}
=============================================

Nicoletta Riva MD

Treatment of unusual site venous thromboembolism (VTE) can be challenging, due to the relative rarity of these thromboses and the paucity of strong evidence in the literature. Patients with unusual VTE were not included in the large phase 3 trials assessing the direct oral anticoagulants (DOACs), but several case series, retrospective and prospective studies, and two small randomized controlled trials[^44^](#rth212368-bib-0044){ref-type="ref"}, [^45^](#rth212368-bib-0045){ref-type="ref"} were recently published. Currently available results suggest that the safety and effectiveness of the DOACs in upper‐extremity deep vein thrombosis (UEDVT)[^46^](#rth212368-bib-0046){ref-type="ref"} is comparable to lower‐limb deep vein thrombosis and pulmonary embolism. Studies in splanchnic vein thrombosis (SVT) and cerebral vein thrombosis (CVT) showed promising results, although hampered by low number of patients, variable study design and outcome definitions, and heterogeneity of results, which resulted in a wide range of the major clinical outcomes. A number of ongoing studies will provide further evidence on unusual VTE.

Tyrosine kinases‐phosphatases and platelet activation {#rth212368-sec-0027}
=====================================================

Yotis Senis MSc, PhD

Platelet activation is a tightly controlled process, allowing platelets to respond rapidly to vascular injury, while preventing pathological thrombosis. Reversible tyrosine phosphorylation is a primary mode of signal transduction catalyzed by the opposing activities of protein‐tyrosine kinases (PTKs) and phosphatases (PTPs), mediating binding of Src homology 2 (SH2) domain‐containing proteins to phosphotyrosine residues (p‐Tyr), and altering the catalytic activity of enzymes. Src family kinases (SFKs) are essential for initiating and propagating signals from a diverse repertoire of platelet receptors, including GPVI‐FcR γ‐chain, GPIb‐IX‐V, P2Y~12~, αIIbβ3 and G6b‐B.[^47^](#rth212368-bib-0047){ref-type="ref"} The structurally distinct PTKs spleen tyrosine kinase (Syk) and Bruton's tyrosine kinase (Btk) play vital roles in amplifying activation signals, whereas C‐terminal Src kinase (Csk) and Csk homologous kinase (Chk) inhibit SFK activity.[^48^](#rth212368-bib-0048){ref-type="ref"} PTPs are equally important regulators of platelet activation, notably, the PTP receptor‐type J (PTPRJ, also referred to CD148), which both activates and attenuates SFK activity[^48^](#rth212368-bib-0048){ref-type="ref"}; and the nontransmembrane SH2 domain‐containing PTPs 1 and 2 (Shp1, Shp2), critical for transmitting inhibitory signals from G6b‐B.[^49^](#rth212368-bib-0049){ref-type="ref"} Understanding the molecular interplay between PTKs and PTPs has important scientific and clinical implications, as tyrosine kinase inhibitors are increasingly used clinically, and tyrosine phosphatase inhibitors come into use.

DOACs in children: Current evidence and future perspectives {#rth212368-sec-0029}
===========================================================

Cornelia H. van Ommen MD, PhD

The first phase 3 direct oral anticoagulant (DOAC) study for the treatment of pediatric venous thromboembolism (VTE) showed similar safety and efficacy in the rivaroxaban and standard of care groups.[^50^](#rth212368-bib-0050){ref-type="ref"} Consequently, DOACs will probably become the anticoagulants of choice in children. However, certain limitations should be considered. In the rivaroxaban trial, only 37 children \<2 years were included. Neonates had to have a gestational age of at least 37 weeks and oral feeding for 10 days; most neonates with VTE will not meet this requirement. Heavy menstrual bleeding, frequently seen in female DOAC users, may be a problem for adolescents with estrogen‐associated VTE. Finally, adherence issues with DOACs might be a reason to switch back to "old‐fashioned" anticoagulants to increase contact between patients and caregivers. Consequently, postauthorization studies are needed, which require international registries such as the Throm‐PED registry.[^51^](#rth212368-bib-0051){ref-type="ref"} At present, antithrombotic treatment in children requires a personalized approach.

PAI‐1 and the multimorbidity of aging {#rth212368-sec-0030}
=====================================

Douglas E. Vaughan MD

Plasminogen activator inhibitor‐1 (PAI‐1) is a functional mediator of cellular senescence. Experimental evidence has uncovered direct mechanistic links between PAI‐1 and aging‐like pathology. Conversely, PAI‐1 deficiency provides protection against aging‐related pathologies in experimental models. Furthermore, in healthy human populations, plasma PAI‐1 predicts the development of vascular stiffness, coronary disease, diabetes, and hepatic steatosis. We have shown that PAI‐1 deficiency protects against emphysema and arteriosclerosis and quadruples life span in a mouse model that resembles accelerated human aging. In a remarkable "natural" randomized study in humans, heterozygous carriers of a null variant in the gene that codes for PAI‐1 (*SERPINE*1) have longer telomeres, lower fasting insulin levels, protection from diabetes, preserved vascular flexibility, and a longer life span than their unaffected kindred. Based on experimental evidence in cells and mice, epidemiologic studies, and findings in a unique human population, PAI‐1 is a validated target for the prevention of numerous aging‐related morbidities and perhaps even aging itself.[^52^](#rth212368-bib-0052){ref-type="ref"}, [^53^](#rth212368-bib-0053){ref-type="ref"}, [^54^](#rth212368-bib-0054){ref-type="ref"}

Visualizing thrombosis to improve thrombolysis {#rth212368-sec-0031}
==============================================

John Weisel PhD
